Prospective Descriptive Study of Injuries Associated to Anterior Shoulder Dislocations in Patients Over 40 Years
- Conditions
- Anterior Glenohumeral Dislocations
- Interventions
- Procedure: Reduction
- Registration Number
- NCT05898243
- Lead Sponsor
- Corporacion Parc Tauli
- Brief Summary
The glenohumeral joint has the highest rate of dislocation of the whole body, due to its high mobility and the special characteristics of its anatomy. It is estimated that every year between 1-2% of the population will suffer from glenohumeral dislocation. The vast majority of studies are based on young patients under the age of 40, given that at this age they have the higher incidence and at the same time, they have higher redislocation index. However, the investigators are in front of a more active population with a longer life expectancy. That is why the cases of anterior glenohumeral dislocations are increasing in people older than 40 years. Given that most studies focus on younger patients, the investigators lack knowledge about which injuries are associated with dislocation at this age and whether these influence its clinical evolution.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 120
- More than 40 years old
- First episode of traumatic anterior gelnohumeral dislocation seen in Rx
- Acceptance to be checked over 2 years
- Acceptance to be submitted to TAC, NMR, EMG and Bilateral Ultrasound
- Previous fractures in this extremity
- Previous neurovascular lesions in this extremity
- Other associated lesions
- Cognitive alterations or dementia which prevent completing the protocols. Patients with <14 points in Mini-mental test.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Humeral anterior dislocation Reduction Patients presenting a first episode of humeral anterior dislocation and who are over 40 years old.
- Primary Outcome Measures
Name Time Method Characterization of associated lesions At the three months visit including assessment of NMR/EMG/TAC/Bilateral Ultrasound
- Secondary Outcome Measures
Name Time Method Type of treatment 3, 6, 12 and 24 months Constant Functional Test 3, 6, 12 and 24 months WOSI test 3, 6, 12 and 24 months SST 3, 6, 12 and 24 months Redislocations 3, 6, 12 and 24 months
Trial Locations
- Locations (1)
Hospital Parc Taulí
🇪🇸Sabadell, Barcelona, Spain